氘可来昔替尼(Deucravacitinib)在哪里买比较靠谱？

Introduction: Deucravacitinib is a once-daily oral tyrosine kinase 2 (TYK2) blocker indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy (phototherapy).

Deucravacitinib works by blocking an immune system protein called TYK2, which plays a role in inflammation and is associated with plaque psoriasis. Blocking TYK2 improves psoriasis symptoms and reduces the severity and number of psoriasis lesions.

Where to buy Deucravacitinib more reliably

The most reliable channels for purchasing Deucravacitinib are as follows.

1. Hospital pharmacies: Many large hospitals have drug supplies in pharmacies or clinics. Patients can consult hospitals near their city to find out whether deuterated colexitinib is available for purchase.

2. Online pharmacies: With the development of the Internet, many online pharmacies have begun to provide sales services of various prescription drugs. Patients can search for deuterated colexitinib in reputable online pharmacies and be sure to choose an online pharmacy with a good reputation and certification for purchase.

3. Physical pharmacies: Patients can also purchase deuterated coxitinib through physical pharmacies. A medical prescription is usually required before purchase.

Deuterated colexitinib is a prescription drug and needs to be used under the guidance of a doctor. It is recommended to consult a doctor and obtain a prescription before purchasing. At the same time, be sure to choose formal channels when purchasing to ensure the authenticity and safety of the drugs.

Special population use of Deucravacitinib

1. Pregnant women: The available data in case reports on the use of Deucravacitinib during pregnancy are insufficient to assess the risk of drug-related major birth defects, miscarriage, or adverse maternal and fetal outcomes. Pregnant women are generally not recommended to take Deucravacitinib.

2. Breastfeeding women: There is currently no data on whether deuterated colexitinib appears in human milk, its impact on breastfed infants, or its impact on milk production. Deuterated colexitinib is present in rat milk, and when a drug is present in animal milk, it is likely that the drug is also present in human milk. The developmental and health benefits of breastfeeding should be considered, as well as the mother's clinical need for colexitinib or any potential adverse effects of underlying maternal disease on the breastfed infant.

Efficacy of Deucravacitinib

POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two 52-week, multicenter, randomized, double-blind, placebo- and active-controlled Phase 3 studies designed to evaluate the safety and efficacy of deuterated colexitinib in adult patients with moderate to severe plaque psoriasis.

Percentage of patients achieving PASI 75 at Week 16 compared with placebo, and percentage of patients achieving sPGA 0/1 at Week 16 compared with placebo. Results for PASI 75 (POETYK PSO-1: 58% vs 13%; POETYK PSO-2: 53% vs 9%) and sPGA0/1 (POETYK PSO-1: 54% vs 7%; POETYK PSO-2: 50% vs 9%) were achieved.

Assess patients for active and latent tuberculosis before initiating treatment with deuterated colexitinib, update immunizations according to current immunization guidelines, and monitor for laboratory abnormalities. Use of deuterated colexitinib is not recommended in patients with severely impaired liver function.